Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan Liposome Plus Concurrent Chemoradiotherapy for Locally Advanced Pancreatic Cancer
ChiCTR2500109809Phase 4Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Sep 2025
- Modality
- Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of irinotecan liposome in pancreatic cancer (PC), sponsored by Henan Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
irinotecan liposome
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on ChiCTR2500109809.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109809.